Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study evaluated a new insulin delivery system designed to reduce insulin delivery when trends in continuous glucose monitoring (CGM) glucose concentrations predict future hypoglycemia. RESEARCH DESIGN AND METHODS: Individuals with type 1 diabetes (n = 103, age 6–72 years, mean HbA1c 7.3% [56 mmol/mol]) participated in a 6-week randomized crossover trial to evaluate the efficacy and safety of a Tandem Diabetes Care t:slim X2 pump with Basal-IQ integrated with a Dexcom G5 sensor and a predictive low-glucose suspend algorithm (PLGS) compared with sensor-augmented pump (SAP) therapy. The primary outcome was CGM-measured time <70 mg/dL. RESULTS: Both study periods were completed by 99% of participants; median CGM usage exceeded 90% in both arms. Median time <70 mg/dL was reduced from 3.6% at baseline to 2.6% during the 3-week period in the PLGS arm compared with 3.2% in the SAP arm (difference [PLGS − SAP] = −0.8%, 95% CI −1.1 to −0.5, P < 0.001). The corresponding mean values were 4.4%, 3.1%, and 4.5%, respectively, represent-ing a 31% reduction in the time <70 mg/dL with PLGS. There was no increase in mean glucose concentration (159 vs. 159 mg/dL, P = 0.40) or percentage of time spent >180 mg/dL (32% vs. 33%, P = 0.12). One severe hypoglycemic event occurred in the SAP arm and none in the PLGS arm. Mean pump suspension time was 104 min/day. CONCLUSIONS: The Tandem Diabetes Care Basal-IQ PLGS system significantly reduced hypoglycemia without rebound hyperglycemia, indicating that the system can benefit adults and youth with type 1 diabetes in improving glycemic control.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Partial closed-loop therapy, such as predictive low-glucose suspend (PLGS) technology, has been shown in nonpregnant people to be better than sensoraugmented insulin pumps (SAP) for reducing low glucose values (108).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [108]
In the citing paper
“Both generation 1 low-glucose-suspend33 and generation 2 hybrid closed-loop systems improve glycated haemoglobin concentrations, the time in target range and the time below target range in children, adolescents34 and adults.35-37”
From Blood glucose monitoring devices: current considerations (2023) · cites this paper as [33]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [25]
In the citing paper
“Predictive lowglucose suspend systems have been shown to reduce time spent with glucose <70 mg/dL without rebound hyperglycemia during a 6-week randomized crossover trial (190).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [190]
Citations
Cites
Adaptive linear step-up procedures that control the false discovery rate
Benjamini, Y., Krieger, A. M., & Yekutieli, D. (2006) · Biometrika · doi:10.1093/biomet/93.3.491 · Cited by 3,228 · cited 1×
“All nominal (uncorrected) P values except those from the primary and safety analyses were adjusted for multiple comparisons using the Benjamini-Hochberg adaptive false discovery procedure (24).”
MethodInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“Percentage of time,54 mg/dL was added as a post hoc outcome to conform with a recent consensus classification of hypoglycemia (21).”
MethodSelf-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Estimates of Location Based on Rank Tests
Hodges, J. L., & Lehmann, E. L. (1963) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177704172 · Cited by 1,260 · cited 1×
“parametric analysis based on ranks was performed (23).”
MethodMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 5×
“ticipants using an insulin pump and CGM before the study were higher and baseline HbA1c levels were lower than the national averages for adults and children with type 1 diabetes (9).”
BackgroundInfluentialSelf-citationThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“8% fewer nocturnal hypoglycemia events using a threshold suspend system compared with sensor-augmented pump (SAP) therapy (10).”
MethodSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Determining what individual SUS scores mean
(2009) · Journal of Usability Studies archive · doi:10.5555/2835587.2835589 · Cited by 412
Cited by
Items 101–200 of 247
Boscari, F., Ferretto, S., Cavallin, F., & Bruttomesso, D. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109784 · Cited by 30
Rosales, N., Battista, H. D., & Garelli, F. (2021) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2021.103106 · Cited by 30
Recent advances in closed-loop insulin delivery
Ware, J., & Hovorka, R. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154953 · Cited by 31
Müller, L., Habif, S., Leas, S., & Aronoff-Spencer, E. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0190 · Cited by 24
Alotaibi, A., Khalifah, R. A. A., & McAssey, K. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13088 · Cited by 27
“8 mmol/L (<50 mg/ dL)/24 hours duration.(9,10,13) The result showed a statistically significant reduction of severe hypoglycemia in favor of the PLGS system with MD of −0.”
BackgroundMethodResultInfluentialA clinical review of the t:slim X2 insulin pump
Berget, C., Lange, S. L., Messer, L. H., & Forlenza, G. P. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1814734 · Cited by 27
Self-citation2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
Ko, S. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.4.244 · Cited by 23
Beyond A1C: exploring continuous glucose monitoring metrics in managing diabetes
Friedman, J. G., Coyne, K., Aleppo, G., & Szmuilowicz, E. D. (2023) · Endocrine Connections · doi:10.1530/ec-23-0085 · Cited by 22
Nallicheri, A., Close Concerns, S. F., Mahoney, K. M., Close Concerns, S. F., Gutow, H. A., Close Concerns, S. F., Bellini, N. J., & Isaacs, D. M. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.27 · Cited by 24
“9% in TIR, respectively, while not experiencing any hypoglycaemic or diabetic ketoacidosis events.(27) All studies involving Omnipod 5 from our review are compiled in Table 4.”
BackgroundRidder, F. D., den Brinker, M., & Block, C. E. M. D. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819865399 · Cited by 23
Pinsker, J. E., Leas, S., Müller, L., & Habif, S. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0554 · Cited by 22
Self-citationAddala, A., Zaharieva, D. P., Gu, A., Prahalad, P., Scheinker, D., Buckingham, B. A., Hood, K. K., & Maahs, D. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab522 · Cited by 23
Self-citationDevelopment and Future of Automated Insulin Delivery (AID) Systems
Garg, S. K., & MCVEAN, J. J. F. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0467 · Cited by 28
Pinsker, J. E., Bartee, A., Katz, M., Lalonde, A., Jones, R., Dassau, E., & Wolpert, H. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0619 · Cited by 21
Self-citationA Virtual Training Program for the Tandem t:slim X2 Insulin Pump: Implementation and Outcomes
Pinsker, J. E., Singh, H., McElwee-Malloy, M., Constantin, A., LEAS, S. A., Kriegel, K., & HABIF, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0602 · Cited by 21
“11 16 Yet there has been a tremendous increase in telemedicine visits since the start of the COVID-19 pandemic.”
Self-citationPuhr, S., Derdzinski, M., Parker, A. S., Welsh, J. B., & Price, D. A. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819840691 · Cited by 20
Anandhakrishnan, A., & Hussain, S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15920 · Cited by 28
“91 When AID systems targeting hypoglycaemia were compared with SAP, LGS devices were shown to improve hypoglycaemia without increases in HbA1c, 33,92 and PLGS were shown to reduce the severity and duration of hypoglycaemia, 35,93 with resultant QoL benefits in pwT1D.”
Evidence from clinical trials on high-risk medical devices in children: a scoping review
Guerlich, K., Patro-Gołąb, B., Dworakowski, P., Fraser, A. G., Kammermeier, M., Melvin, T., & Koletzko, B. V. (2023) · Pediatric Research · doi:10.1038/s41390-023-02819-4 · Cited by 17
Felix dies natalis, insulin… ceterum autem censeo “beta is better”
Piemonti, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01737-3 · Cited by 18
Urakami, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030781 · Cited by 19
Lunati, M. E., Morpurgo, P. S., Rossi, A., Gandolfi, A., Cogliati, I., Bolla, A. M., Plebani, L., Vallone, L., Montefusco, L. B., Pastore, I., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816599 · Cited by 18
Ekhlaspour, L., Tabatabai, I., & Buckingham, B. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819851790 · Cited by 17
“Tandem’s Basal:IQ predictive low glucose suspend (PLGS) system was also approved by FDA for patients older than six years of age in June 2018.(29) Tandem aims for approval of their Control:IQ HCL system in the second half of 2019.”
Self-citationGlycemic Status Assessment by the Latest Glucose Monitoring Technologies
Malandrucco, I., Russo, B., Picconi, F., Menduni, M., & Frontoni, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218243 · Cited by 17
“In addition, it has been recently demonstrated that the use of SAP with PLGS reduces hypoglycemia events and duration in T1D patients [74].”
BackgroundThe Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes
Inoue, R., Nishiyama, K., Li, J., Miyashita, D., Ono, M., Terauchi, Y., & Shirakawa, J. (2021) · Cells · doi:10.3390/cells10071589 · Cited by 23
“Blood glucose monitoring using continuous glucose monitoring (CGM) or flush glucose monitoring (FGM) and insulin pumps with a Predictive Low Glucose Suspend (PLGS) function has helped to better maintain blood glucose levels [51,52].”
Hood, K. K., Polonsky, W. H., MacLeish, S. A., Levy, C. J., Forlenza, G. P., Criego, A. B., Buckingham, B. A., Bode, B. W., Hansen, D. W., Sherr, J. L., et al. (2023) · Pediatric Diabetes · doi:10.1155/2023/8867625 · Cited by 21
“Te System Usability Scale (SUS) is a validated questionnaire to assess perceived usability of technologies across industries [22, 23], including diabetes technology [24, 25].”
Self-citationWildevuur, S. E., Simonse, L. W. L., Groenewegen, P., & Klink, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025930 · Cited by 16
Messer, L. H., Campbell, K., Pyle, L. L., & Forlenza, G. P. (2020) · Diabetic Medicine · doi:10.1111/dme.14381 · Cited by 15
Self-citationSchöttler, H., Auzanneau, M., Best, F., Braune, K., Freff, M., Heidtmann, B., Jung, R., Karges, B., Klee, D., Müller, A., et al. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1259-1190 · Cited by 15
“[28] Forlenza GP, Li Z, Buckingham BA et al.”
BackgroundMacLeish, S. A., Hood, K. K., Polonsky, W. H., Wood, J., Bode, B. W., Forlenza, G. P., Laffel, L. M., Buckingham, B. A., Criego, A. B., Schoelwer, M. J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15906 · Cited by 14
“35,36 This questionnaire was used to assess the caregiver's perceived usability of the system, as the care-giver is the primary user of the system for this age group.”
Self-citationClosed-loop insulin delivery systems in children and adolescents with type 1 diabetes
Dovč, K., & Battelino, T. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1713747 · Cited by 15
Decision Support Systems and Closed Loop
Nimri, R., Ochs, A. R., Pinsker, J. E., Phillip, M., & Dassau, E. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.2504 · Cited by 13
“Bally L 1,2,3 , Thabit H 3,6,7 , Hartnell S 5 , Andereggen E 1 , Ruan Y 3 , Wilinska ME 3,4 , Evans ML 3,5 , Wertli MM 2 , Coll AP 3,5 , Stettler C 1 , Hovorka R 3,4 Departments of 1”
Self-citationMaida, E., Caruso, P., Bonavita, S., Abbadessa, G., Miele, G., Longo, M., Scappaticcio, L., Ruocco, E., Trojsi, F., Esposito, K., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124240 · Cited by 22
“These technologies initially enabled the glucose-responsive regulation of insulin delivery to address hypoglycemia [46,47].”
How Well Do Continuous Glucose Monitoring Systems Perform During Exercise?
Castle, J. R., & Rodbard, D. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0132 · Cited by 12
Roze, S., Smith‐Palmer, J., de Portu, S., Saltik, A. Z. O., Akgül, T., & Deyneli, O. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0198 · Cited by 11
“35 In addition, as noted previously, sensor technology is continually evolving, meaning that, for example, in future years, sensors that can be worn for durations considerably longer than 6 days days may become available; however, as such advances are speculative, these were not captured in this…”
Alfadli, S. F., Alotaibi, Y. S., Aqdi, M. J., Almozan, L. A., Alzubaidi, Z. B., Altemani, H. A., Almutairi, S. D., Alabdullah, H. A., Almehmadi, A. A., Alanzi, A. L., et al. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100382 · Cited by 16
“Our literature search identified 27 studies including 2975 participants that met our inclusion criteria and were included in the meta-analysis ( [ 12 – 38 ] ) (”
Addressing disparities in technology use among patients with type 1 diabetes: a review
Kanbour, S., & Everett, E. M. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000840 · Cited by 13
Artificial Pancreas Technology Offers Hope for Childhood Diabetes
Schoelwer, M. J., & DeBoer, M. D. (2021) · Current Nutrition Reports · doi:10.1007/s13668-020-00347-9 · Cited by 11
Montaser, E., Díez, J.-L., & Bondía, J. (2021) · Sensors · doi:10.3390/s21093188 · Cited by 12
“In sensor-pump integrated systems, predicted glucose levels can trigger actions by the insulin pump, like automatic insulin infusion suspension to mitigate impending hypoglycemia [4].”
BackgroundInsulin Titration Guidelines for Patients With Type 1 Diabetes: It Is About Time!
Walsh, J. S. A., Roberts, R., Bailey, T. S., & Heinemann, L. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221087261 · Cited by 12
“This review (1) details the widespread problems generated by nonphysiological dose settings in today’s BCs, insulin pumps, and AID systems; (2) presents a method to develop and implement optimized total daily doses of insulin to correct the most common problem of hyperglycemia; (3) discusses using large device databas…”
MethodReduced hypoglycaemia using liver‐targeted insulin in individuals with type 1 diabetes
Weinstock, R. S., Bode, B. W., Garg, S. K., Klonoff, D. C., Sanadi, C. E. E., Geho, W. B., Muchmore, D. B., & Penn, M. S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14761 · Cited by 11
“Level 2 hypoglycaemic events were derived from CGM records, as previously described.(17) Briefly, the beginning of a level 2 event was defined by three consecutive measures (15 minutes) of blood glucose less than 54 mg/dl.”
MethodAkiyama, T., Yamakawa, T., Orime, K., Ichikawa, M., Harada, M., Netsu, T., Akamatsu, R., Nakamura, K., Shinoda, S., & Terauchi, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14103 · Cited by 13
“The PLGS sys-tem reduced the percentage of time below blood glucose range (TBR) of 70 mg/dL without increasing that of time above blood glucose range (TAR) of 180 mg/dL, predominantly in individuals of European ancestry 3 .”
BackgroundGaweł, W., Deja, G., Kamińska, H., Tabor, A., Skała‐Zamorowska, E., & Jarosz-Chobot, P. A. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12944 · Cited by 13
“Hyperglycemia following insulin suspension was also avoided in the study by Forlenza et al.(18) In this study however, the algorithm for the resumption of insulin administration was more aggressive.”
BackgroundCorathers, S. D., & DeSalvo, D. J. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0017 · Cited by 15
Where Do We Stand with Closed-Loop Systems and Their Challenges?
Jackson, M. A., & Castle, J. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0469 · Cited by 13
Aleppo, G., Parkin, C. G., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., Umpierrez, G. E., Forlenza, G. P., & McGill, J. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0196 · Cited by 11
Self-citationBlood glucose monitoring devices: current considerations
Sly, B., & Taylor, J. (2023) · Australian Prescriber · doi:10.18773/austprescr.2023.013 · Cited by 11
Tsunemi, A., Sato, J., Kurita, M., Wakabayashi, Y., WASEDA, N., Koshibu, M., Shinohara, M., Ozaki, A., Nakamura, H. K., Hirano, N., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13288 · Cited by 10
Continuous Subcutaneous Insulin Infusions: Closing the Loop
Díaz-Balzac, C. A., Pillinger, D., & Wittlin, S. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac746 · Cited by 11
Glycometabolic outcomes in adult type 1 diabetic patients switching to closed-loop systems
Papa, G. F. S., Cannarella, R., Condorelli, R. A., Finocchiaro, C., Calogero, A. E., & Vignera, S. L. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110907 · Cited by 11
Nandam, N., Thung, S., Venkatesh, K. K., Gabbe, S. G., Ma, J., Peng, J., Dungan, K. M., & Buschur, E. (2024) · Cureus · doi:10.7759/cureus.52369 · Cited by 15
JENDLE, J. H., Adolfsson, P., & Pollock, N. W. (2020) · Diving and Hyperbaric Medicine Journal · doi:10.28920/dhm50.2.135-143 · Cited by 10
Automated Insulin Delivery in Children with Type 1 Diabetes.
Cengiz, E. (2020) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2019.10.012 · Cited by 7
Self-citationLei, M., Chen, D., Ling, P., Wang, C., Yang, D., Deng, H., Yang, X., Xu, W., & Yan, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15357 · Cited by 8
Diabetes technology: A primer for clinicians
Ambalavanan, J., Isaacs, D. M., & Lansang, M. C. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23073 · Cited by 8
Barnard-Kelly, K. D., Marrero, D. G., de Wit, M., Pouwer, F., Khunti, K., Hermanns, N., Pierce, J. S., Laffel, L. M., Holt, R. I. G., Battelino, T., et al. (2024) · Diabetic Medicine · doi:10.1111/dme.15484 · Cited by 9
“(37) Elevated caregiver distress is associated with teen distress, teen depression (48), less adaptive parenting styles (50–52) and increased rates of diabetes-specific family conflict (51; 53–56, 17).”
A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes
Galderisi, A., & Sherr, J. L. (2019) · Pediatric Annals · doi:10.3928/19382359-20190725-03 · Cited by 8
Pancreas transplant versus islet transplant versus insulin pump therapy: in which patients and when?
Tamburrini, R., & Odorico, J. S. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000857 · Cited by 9
Sperling, M. A., Wolfsdorf, J. I., Menon, R. K., Tamborlane, W. V., Maahs, D. M., Battelino, T., & Phillip, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00021-x · Cited by 13
Berget, C., & Wyckoff, L. (2020) · NASN School Nurse · doi:10.1177/1942602x20928914 · Cited by 8
Daytime hypoglycemic episodes during the use of an advanced hybrid closed loop system
Rossi, A., Montefusco, L. B., Reseghetti, E., Pastore, I., Rossi, G., Usuelli, V., Loretelli, C., Boci, D., Nasr, M. B., D’Addio, F., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111011 · Cited by 7
Kladov, D. E., Berikov, V., Semenova, J. F., & Klimontov, V. V. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13101454 · Cited by 6
“Switching to subcutaneous continuous insulin infusion with sensor-augmented pumps or closed-loop control systems may be another option for patients with an increased risk of NH [32–34].”
BackgroundClinical Considerations for Insulin Therapy in Older Adults with Type 1 Diabetes
Gandhi, G. Y., & Mooradian, A. D. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00900-3 · Cited by 12
Blood Glucose Prediction Algorithms Require Clinically Relevant Performance Criteria Beyond Accuracy
Wolff, M. K., Schaathun, H. G., Gros, S., Volden, R., Steinert, M., & Fougner, A. L. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0074 · Cited by 8
“25 Notethatthetuningoftherapysettingsinthisimplemen-tationisdeliberatelysimpli fi ed.”
Bukara-Radujković, G., & Miljković, V. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1388245 · Cited by 6
Automated insulin delivery systems in elderly patients with brittle type 2 diabetes
Çaklılı, Ö. T., Cetin, F., Özkan, M. K., Şahiner, E., Çakmak, R., Keskin, E., Hacışahinoğulları, H., Goncuoglu, E. S., & Yilmaz, M. T. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111913 · Cited by 5
Delgado, A. M., & Lucas, F. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2023.08.005 · Cited by 5
Xu, T., Jost, E., Messer, L. H., Cook, P. F., Forlenza, G. P., Sankaranarayanan, S., Fiesler, C. L., & Voida, S. (2024) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3613904.3642612 · Cited by 10
“Managing T1D involves attending to and exerting control over complex and dynamic aspects of personal life (e.g., diet and activity) and administering medication day and night [17, 29, 47].”
BackgroundInfluentialSelf-citationSuboptimally Controlled Diabetes in Pregnancy: A Review to Guide Antepartum and Delivery Management
Cate, J. J. M., Bloom, E. A., Chu, A., Bauer, S., Kuller, J. A., & Dotters-Katz, S. K. (2024) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001270 · Cited by 7
Rodacki, M., Calliari, L. E., Ramalho, A. C., Vianna, A. G. D., Franco, D. R., Melo, K., Araujo, L. R., Krakauer, M., Scharf, M., Minicucci, W. J., et al. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00607-2 · Cited by 8
“the downward arrows for hypoglycemia prevention [3].”
Armiger, R., Reddy, M., Oliver, N. S., Georgiou, P., & Herrero, P. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211060074 · Cited by 5
Telliam, C., & Thivolet, C. H. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.05.010 · Cited by 6
Predictive Low Glucose Suspend Algorithm in Real Life: A Five-Year Follow-Up Retrospective Analysis
Tubili, C., Pollakova, D., Nardone, M. R., & Folco, U. D. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820952107 · Cited by 5
“median follow-up of 12 months (6-18), but the reduction of HbA1c was not significant (by 0.”
BackgroundJoubert, M., Briant, A. R., Kessler, L., Fall-Mostaine, F., Dubois, S. G., Guerci, B., Schoumacker-Ley, L., Reznik, Y., & Parienti, J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01302-3 · Cited by 5
“[7, 8, 13, 14], and only two demonstrating a reduction in this parameter [9, 15].”
BackgroundResultShah, V. N., Rewers, A. H., & Garg, S. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816714-4.00013-2 · Cited by 4
Technologies in the management of type 1 diabetes
SNAITH, J. R., & Holmes-Walker, D. J. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.50946 · Cited by 4
Automated Adaptation of Insulin Treatment in Type 1 Diabetes
Fabris, C., Gautier, T., & Breton, M. D. (2021) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc46164.2021.9630191 · Cited by 7
“In this context, despite the improving accuracy of glucose monitoring devices [2],[3], the availability of modern insulin analogs [4], and the growing proliferation of new technologies [3],[5]-[7], glycemic control remains a challenge in T1D [8], with complication rates and excess mortality still significantly higher…”
BackgroundKubota, S., Sato, A., Hosokawa, M., Okubo, Y., Takayama, S., Kaneko, A., Shimada, Y., Asano, Y., Sato, Y., Yamazaki, M., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0136 · Cited by 4
Barriers to access to insulin pumps in Chile: A qualitative study of a high-cost technology
Cabieses, B., V, Alexandra Obach, K., Madrid, P., & Paredes-Fernández, D. (2025) · Health Policy and Technology · doi:10.1016/j.hlpt.2025.100992 · Cited by 3
Lee, J., Rachim, V. P., & Park, S. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.108589 · Cited by 3
Moreno-Fernández, J., Beato-Víbora, P. I., Olvera, P., García-Seco, J. A., Gallego-Gamero, F., Herrera, M. T., & Muñoz‐Rodríguez, J. R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109093 · Cited by 3
Hybrid Closed-Loop Insulin Delivery Systems for People With Type 1 Diabetes
Service, C. H. T. A. (2021) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2021.50 · Cited by 4
Kowalczyk, E., & Szypowska, A. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01310-y · Cited by 3
Artificial intelligence in diabetes management
Thomas, A., Gopi, V. P., & Francis, B. (2024) · Advances in Artificial Intelligence · doi:10.1016/b978-0-443-19073-5.00002-1 · Cited by 3
Honoki, H., Yagi, K., Tsuda, S., Wada, T., Enkaku, A., Nakagawa‐Yokoyama, M., Kamigishi, M., Shikata, M., Takikawa-Nishiday, A., Fujisaka, S., et al. (2021) · Diabetology International · doi:10.1007/s13340-020-00489-9 · Cited by 5
“SAP-PLGS makes it possible to avoid severe hypoglycemia following the compensation of insulin to mitigate transient hyperglycemia [10, 11].”
BackgroundInfluentialSawyer, A., Forlenza, G. P., & Wadwa, R. P. (2025) · Expert Review of Medical Devices · doi:10.1080/17434440.2025.2585061 · Cited by 2
“It predicted low glucose and automatically suspended insulin delivery to prevent hypoglycemia and was shown to be safe and effective [47,48].”
Self-citationArtificial intelligence in critically ill diabetic patients: current status and future prospects
Juneja, D., Gupta, A., & Singh, O. (2022) · Artificial Intelligence in Gastroenterology · doi:10.35712/aig.v3.i2.66 · Cited by 3
The implementation of modern technology into standard of care of type 1 diabetes
Petruželková, L., Plachý, L., Kajprová, M., Neuman, V., Obermannová, B., Průhová, Š., Lebl, J., Koloušková, S., & Šumník, Z. (2022) · Česko-slovenská pediatrie · doi:10.55095/cspediatrie2022/010 · Cited by 2
Dodesini, A. R., Elena, C., Anna, C., Scaranna, C., Rosalia, B., Mascia, A., Silvia, B., Borella, N. D., Giuseppe, L., & Trevisan, R. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02080-5 · Cited by 2
Clinical Practice Update: Inpatient Insulin Pump and Integrated Insulin Delivery Systems
Nguyen, S., Davis, G. M., & Vasudevan, M. M. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_7 · Cited by 2
Tamura, R. K., Kodani, N., Itoh, A., Meguro, S., Kajio, H., & Itoh, H. (2024) · Diabetology International · doi:10.1007/s13340-024-00716-7 · Cited by 2
“SAP with PLGS reduced hypoglycemia without deterioration in HbA1c levels, resulting in further treatment satisfaction of the users [29–33].”
Dispositivi indossabili per la gestione del diabete
Carlucci, F., Tabucchi, A., Fiorini, M., Galasso, L., & Terreni, A. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00067-6 · Cited by 2
Advances in Pharmacotherapeutics, Metabolic Surgery, and Technology for Diabetes
Guerron, A. D., Davis, G. M., & Pasquel, F. J. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.009 · Cited by 2
Update Typ-1-Diabetes bei Kids: Insuline, Technologie, Telemedizin
Kapellen, T. M. (2021) · Info Diabetologie · doi:10.1007/s15034-021-3755-4 · Cited by 2
“Dieses System arbeitet in Kombination mit einem DexcomSensor [18].”
BackgroundModelado y simulación de tecnologías para el tratamiento de la diabetes
Rosales, N. (2020) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/97299 · Cited by 7
2023 Clinical Practice Guidelines for Diabetes: Continuous Glucose Monitoring and Insulin Pumps
Jin, S. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.141 · Cited by 1
“그러나 연속혈당측정 기기의 상시적 사용에도 불구 하고 여전히 저혈당 위험이 높은 1형당뇨병 성인에게서는 연 속혈당측정센서와 연동되어 일정한 한도 아래로 혈당이 낮 아지거나(low glucose suspend, LGS), 30분 후 낮아질 것 으로 예측하는 경우 인슐린주입을 멈추는(predictive LGS, PLGS) 알고리듬이 적용된 형태의 센서강화인슐린펌프를 사 용하는 것이 저혈당 위험을 더욱 감소시킬 수 있음이 알려져 있다[8,29,30].”
Using Diabetes Technology in Hospitalized Patients
McCrea, D. L. (2024) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2024.07.001 · Cited by 1
Sidki, A., HIGHTON, P. J., O’Mahoney, L. L., & Wilkinson, T. J. (2026) · Diabetic Medicine · doi:10.1111/dme.70210 · Cited by 1
Diabetes Device Downloading: Benefits and Barriers Among Youth With Type 1 Diabetes
Palmer, B. A., Soltys, K., Zimmerman, M. B., Norris, A. W., Tsalikian, E., Tansey, M., & Pinnaro, C. T. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211059537 · Cited by 1
Problems and methods of a closed-loop blood glucose control system construction
Litinskaia, E. L., Витольдович, П. К., & Zhilo, N. M. (2021) · Journal of Physics Conference Series · doi:10.1088/1742-6596/2091/1/012020 · Cited by 1
Wearable Artificial Pancreas Device Technology
Matsumoto, A. (2024) · Springer eBooks · doi:10.1007/978-981-99-8122-9_12 · Cited by 1
Metadata
- Authors
- Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., Marcal, T., Andre, C., Carria, L., Swanson, V., Lum, J. W., Kollman, C., Woodall, W., & Beck, R. W.
- Affiliations
- University of Colorado Denver (US)
- Jaeb Center for Health Research (US)
- Stanford Medicine (US)
- Sansum Diabetes Research Institute (US)
- Yale University (US)
- Tandem Diabetes Care (United States) (US)
- Corresponding author
- Lum, John W.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-08-08
- Volume
- 41
- Issue
- 10
- Pages
- 2155-2161
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2886691517
- Cited by
- 246
- References
- 32
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 30 · 2023: 32 · 2022: 28 · 2021: 50 · 2020: 38 · 2019: 41 · 2018: 2
- FWCI
- 26.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, hypoglycemia, predictive low glucose suspend, continuous glucose monitoring, insulin pump therapy, sensor-augmented pump, glycemic control, adolescents, children
- MeSH terms
- Adolescent, Adult, Aged, Algorithms, Blood Glucose, Child, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Blood Glucose Self-Monitoring, Drug Delivery Systems, Cross-Over Studies, Monitoring, Ambulatory, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.